Cargando…
Recent Advances and Future Perspectives in Polymer-Based Nanovaccines
Vaccination is the most valuable and cost-effective health measure to prevent and control the spread of infectious diseases. A significant number of infectious diseases and chronic disorders are still not preventable by existing vaccination schemes; therefore, new-generation vaccines are needed. Nov...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226647/ https://www.ncbi.nlm.nih.gov/pubmed/34073648 http://dx.doi.org/10.3390/vaccines9060558 |
_version_ | 1783712336660398080 |
---|---|
author | Pippa, Natassa Gazouli, Maria Pispas, Stergios |
author_facet | Pippa, Natassa Gazouli, Maria Pispas, Stergios |
author_sort | Pippa, Natassa |
collection | PubMed |
description | Vaccination is the most valuable and cost-effective health measure to prevent and control the spread of infectious diseases. A significant number of infectious diseases and chronic disorders are still not preventable by existing vaccination schemes; therefore, new-generation vaccines are needed. Novel technologies such as nanoparticulate systems and adjuvants can enable safe and effective vaccines for difficult target populations such as newborns, elderly, and the immune-compromised. More recently, polymer-based particles have found application as vaccine platforms and vaccine adjuvants due to their ability to prevent antigen degradation and clearance, coupled with enhanced uptake by professional antigen-presenting cells (APCs). Polymeric nanoparticles have been applied in vaccine delivery, showing significant adjuvant effects as they can easily be taken up by APCs. In other words, polymer-based systems offer a lot of advantages, including versatility and flexibility in the design process, the ability to incorporate a range of immunomodulators/antigens, mimicking infection in different ways, and acting as a depot, thereby persisting long enough to generate adaptive immune responses. The aim of this review is to summarize the properties, the characteristics, the added value, and the limitations of the polymer-based nanovaccines, as well as the process of their development by the pharmaceutical industry. |
format | Online Article Text |
id | pubmed-8226647 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82266472021-06-26 Recent Advances and Future Perspectives in Polymer-Based Nanovaccines Pippa, Natassa Gazouli, Maria Pispas, Stergios Vaccines (Basel) Review Vaccination is the most valuable and cost-effective health measure to prevent and control the spread of infectious diseases. A significant number of infectious diseases and chronic disorders are still not preventable by existing vaccination schemes; therefore, new-generation vaccines are needed. Novel technologies such as nanoparticulate systems and adjuvants can enable safe and effective vaccines for difficult target populations such as newborns, elderly, and the immune-compromised. More recently, polymer-based particles have found application as vaccine platforms and vaccine adjuvants due to their ability to prevent antigen degradation and clearance, coupled with enhanced uptake by professional antigen-presenting cells (APCs). Polymeric nanoparticles have been applied in vaccine delivery, showing significant adjuvant effects as they can easily be taken up by APCs. In other words, polymer-based systems offer a lot of advantages, including versatility and flexibility in the design process, the ability to incorporate a range of immunomodulators/antigens, mimicking infection in different ways, and acting as a depot, thereby persisting long enough to generate adaptive immune responses. The aim of this review is to summarize the properties, the characteristics, the added value, and the limitations of the polymer-based nanovaccines, as well as the process of their development by the pharmaceutical industry. MDPI 2021-05-26 /pmc/articles/PMC8226647/ /pubmed/34073648 http://dx.doi.org/10.3390/vaccines9060558 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pippa, Natassa Gazouli, Maria Pispas, Stergios Recent Advances and Future Perspectives in Polymer-Based Nanovaccines |
title | Recent Advances and Future Perspectives in Polymer-Based Nanovaccines |
title_full | Recent Advances and Future Perspectives in Polymer-Based Nanovaccines |
title_fullStr | Recent Advances and Future Perspectives in Polymer-Based Nanovaccines |
title_full_unstemmed | Recent Advances and Future Perspectives in Polymer-Based Nanovaccines |
title_short | Recent Advances and Future Perspectives in Polymer-Based Nanovaccines |
title_sort | recent advances and future perspectives in polymer-based nanovaccines |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226647/ https://www.ncbi.nlm.nih.gov/pubmed/34073648 http://dx.doi.org/10.3390/vaccines9060558 |
work_keys_str_mv | AT pippanatassa recentadvancesandfutureperspectivesinpolymerbasednanovaccines AT gazoulimaria recentadvancesandfutureperspectivesinpolymerbasednanovaccines AT pispasstergios recentadvancesandfutureperspectivesinpolymerbasednanovaccines |